Omnicell (NASDAQ:OMCL) Downgraded to Hold Rating by StockNews.com

Omnicell (NASDAQ:OMCL) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Monday.

A number of other research firms also recently weighed in on OMCL. Wells Fargo & Company decreased their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. JPMorgan Chase & Co. lowered their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday. Bank of America reduced their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, Benchmark reiterated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $51.00.

Omnicell Trading Up 3.5 %

Shares of Omnicell stock traded up $1.20 during trading hours on Monday, hitting $35.14. The company’s stock had a trading volume of 380,919 shares, compared to its average volume of 497,546. The company has a market capitalization of $1.64 billion, a PE ratio of 130.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock has a 50 day moving average of $39.63 and a 200 day moving average of $42.83. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Pier Capital LLC acquired a new stake in shares of Omnicell during the 3rd quarter worth about $5,859,000. Geode Capital Management LLC lifted its holdings in Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after purchasing an additional 2,877 shares during the last quarter. Intech Investment Management LLC bought a new stake in Omnicell in the 3rd quarter valued at $753,000. Shaker Investments LLC OH acquired a new position in Omnicell in the 4th quarter valued at $550,000. Finally, Exchange Traded Concepts LLC increased its position in Omnicell by 6.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock worth $14,232,000 after buying an additional 20,031 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.